
|Articles|August 1, 2003
Transscleral drug delivery system under development
Fort Lauderdale, FL-Efforts to develop an episcleral anecortave acetate transscleral drug delivery system (AA-TSDDD), targeted for patients with age-related macular degeneration (AMD), are progressing initially in the rhesus monkey as preliminary devices are being redesigned to decrease postoperative problems, said Timothy W. Olsen, MD.
Advertisement
Newsletter
Don’t miss out—get Ophthalmology Times updates on the latest clinical advancements and expert interviews, straight to your inbox.
Advertisement
Latest CME
Advertisement
Advertisement
Trending on Ophthalmology Times - Clinical Insights for Eye Specialists
1
AAO 2025: Early optogenetic therapy shows promise for patients with inherited retinal diseases
2
Subretinal drusenoid deposits in Black and Hispanic patients with AMD
3
Starting from scratch on neovascular age-related macular degeneration
4
The mechanics of presbyopia: From muscle movement to functional vision
5